DiagnoCure's partner, Gen-Probe, begins U.S. clinical study of the PROGENSA(R) PCA3 assay

    - A new molecular test to help assess prostate cancer risk -

    Ticker Symbol: CUR

    QUEBEC CITY, Aug. 27 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR) announced
that Gen-Probe, Inc. (NASDAQ:   GPRO), its partner for the development and
commercialization of the PCA3 prostate cancer test, has confirmed today the
beginning of a U.S. clinical study intended to secure U.S. regulatory approval
of the PROGENSA(R) PCA3 assay, a new molecular test that may help determine
the need for a repeat prostate biopsy.
    Gen-Probe anticipates to enroll 500 men, all of whom have had a negative
prostate biopsy, at 10 or more clinical trial sites. The study is expected to
take less than a year, after which, Gen-Probe intends to submit a Premarket
Approval Application (PMA) to the U.S. Food and Drug Administration.
    "We are excited about the announcement made today by our partner as it
represents a decisive step towards maximizing the commercial value of the PCA3
test," stated John C. Schafer, President and Chief Executive Officer of
    To date, more than 20 peer-reviewed publications support the clinical
utility of the PROGENSA PCA3 assay in addressing the well-known limitations of
the PSA (Prostate Specific Antigen) test, currently used by urologists, and
therefore minimizing the unnecessary, costly and invasive biopsies that follow
from "false positive" PSA results.
    According to the American Cancer Society and the Canadian Cancer Society,
218,000 men in the United States and Canada will be diagnosed with prostate
cancer this year, and more than 32,000 men will die from the disease. Prostate
cancer is the second-leading cause of cancer death in men (after lung cancer).

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering laboratory services that
increase clinician and patient confidence in making critical treatment
decisions. DiagnoCure Oncology Laboratories, a subsidiary of DiagnoCure Inc.,
launched in 2008 the Previstage(TM) GCC Colorectal Cancer Staging Test, the
first GCC-based molecular test for the management of colorectal cancer. A
major study published in the February 18, 2009, edition of the Journal of the
American Medical Association demonstrated that GCC, to which DiagnoCure owns
exclusive worldwide diagnostic rights, is the strongest independent predictor
of colorectal cancer recurrence. The Company has a strategic alliance with
Gen-Probe (NASDAQ:   GPRO) for the development and commercialization of a
second-generation prostate cancer test using PCA3, DiagnoCure's proprietary
molecular marker. This test is currently available through laboratories in the
U.S. using PCA3 analyte specific reagents (ASR) from Gen-Probe, in Europe as
the CE-marked PROGENSA(TM) PCA3 in vitro assay, and in Canada. For more
information, visit www.diagnocure.com.

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein unless required by the applicable
securities laws and regulations.
    %SEDAR: 00003671EF

For further information:

For further information: Investors: Jean-François Bureau, CFA, Sr. Vice
President and CFO, DiagnoCure Inc., (418) 527-6100,
communications@diagnocure.com; Media: Paule De Blois, Vice President,
Corporate Affairs, DiagnoCure Inc., (418) 527-6100, p.deblois@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890